VITARKA THERAPEUTICS
Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.
VITARKA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2021-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.vitarka.co.uk
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.27 M GBP
Technology used in webpage:
Euro Pound Sterling Japanese Yen
Similar Organizations
Accelerbiotics
Accelerbiotics develops sustainable solutions for biotechnology and life science field.
DynamX Medical
DynamX Medical has developed a diagnostic system for cancer and pre-cancer.
Dicronis
Dicronis develops microneedles for diagnostic purposes.
M6P Therapeutics
M6P Therapeutics develops biotechnology advances for lysosomal storage diseases.
MeinDoc
E-health startup improving patient understanding of surgical issues
Strataca Systems
Strataca Systems develops patented technology to improve urine output and decrease congestion.
VacV Biotech
VacV Biotech develops an oncolytic virus platform based on the vaccinia virus.
Investors List
Future Planet Capital
Future Planet Capital investment in Seed Round - Vitarka Therapeutics
IndieBio
IndieBio investment in Seed Round - Vitarka Therapeutics
UK Innovation & Science Seed Fund
UK Innovation & Science Seed Fund investment in Seed Round - Vitarka Therapeutics
Innovate UK
Innovate UK investment in Grant - Vitarka Therapeutics
SOSV
SOSV investment in Seed Round - Vitarka Therapeutics
IndieBio
IndieBio investment in Seed Round - Vitarka Therapeutics
SOSV
SOSV investment in Seed Round - Vitarka Therapeutics
Official Site Inspections
http://www.vitarka.co.uk
- Host name: webcluster39.webpod11-cph3.one.com
- IP address: 77.111.240.166
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Vitarka Therapeutics"
Vitarka Therapeutics Ltd
Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets in Oncology, Neuroscience Pain and Neurodegenerative diseases. ... [email protected]. …See details»
Vitarka Therapeutics - Crunchbase Company Profile & Funding
Vitarka Therapeutics may be growing as it has recently raised significant capital, indicating investor confidence and financial resources for expansion. The company secured £1.27 million …See details»
VITARKA THERAPEUTICS LTD Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VITARKA THERAPEUTICS LTD of LONDON. Get the latest business insights from Dun & Bradstreet.See details»
VITARKA THERAPEUTICS LTD - Companies House
GOV.UK Find and update company information Companies House does not verify the accuracy of the information filed (link opens a new window) ... Filing history for VITARKA THERAPEUTICS …See details»
Contact | Vitarka Therapeutics Ltd
ADDRESS Vitarka Therapeutics Ltd Innovation House, Discovery Park Sandwich, Kent CT13 9FF United Kingdom . Name * Email * Message * some-randome-random . GET IN TOUCH. …See details»
Vitarka Therapeutics - VentureRadar
Vitarka Therapeutics is a pre-clinical stage Biotech focused on the development of RNAi therapies and non-viral delivery platform technology. Our combination therapeutics aim to activate the …See details»
VITARKA THERAPEUTICS LTD - Drug pipelines, Patents, Clinical …
Explore VITARKA THERAPEUTICS LTD with its drug pipeline, therapeutic area, technology platform, .See details»
Vitarka - UKI2S - ukinnovationscienceseedfund.co.uk
Https://vitarka.co.uk/ Associated Team Members. ... (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England …See details»
Vitarka Therapeutics Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Vitarka Therapeutics. Use the PitchBook Platform to explore the full profile. Information on valuation, funding, cap tables, investors, and executives for Vitarka …See details»
Vitarka Therapeutics - LinkedIn
Vitarka Therapeutics is delighted to have been selected for the Innovate UK Engineering Biology and Industrial Biotechnology Global Business Innovation Programme focused on San Jose, …See details»
Vitarka Therapeutics Ltd. - Life-Sciences-Europe.com
May 9, 2022 Upcoming Events. Stifel Healthcare Conference 2025 New York; Formnext 2025 Frankfurt am Main; Deutsches Eigenkapitalforum 2025 Frankfurt (German Equity Forum 2025)See details»
Female-led biotech start-up raises £1.27m to develop drug …
Apr 6, 2023 The preclinical biotech start-up Vitarka Therapeutics has secured £1.27m to “revolutionise” intracellular drug delivery through tumour-targeted technology. Founded in …See details»
UK biotech start-up secures £1.27 million to revolutionise ...
Apr 11, 2023 UK biotech start-up secures £1.27 million to revolutionise intracellular drug delivery through tumour-targeted technology A female-led preclinical biotech start-up Vitarka …See details»
Vitarka Therapeutics - SOSV
Apr 3, 2023 Vitarka Therapeutics is a pre-clinical stage biotech focused on developing RNAi therapies using a proprietary non-viral delivery platform. The underlying technology utilizes …See details»
Vitarka Therapeutics - Products, Competitors, Financials, …
Vitarka.co.uk. Overview & Products; Financials; Founded Year 2021. Stage Grant | Alive. Total Raised $1.93M. Mosaic Score. The Mosaic Score is an algorithm that measures the overall …See details»
Vitarka Therapeutics appoints Dr. John Beadle as Chairman of the …
London, November 2024: Vitarka Therapeutics Ltd, the EndoPore® cancer therapeutics company, today announced the appointment of Dr. John Beadle as the new Chairman of the …See details»
GtR - Research Councils UK
Vitarka is a UK life sciences technology SME which is developing a novel intracellular delivery technology, EndoPore. EndoPore is a drug delivery technology which will carry RNA …See details»
UK biotech start-up secures £1.27M to revolutionise intracellular …
Apr 6, 2023 A female-led preclinical biotech start-up Vitarka Therapeutics, focused on revolutionising the market for non-viral drug delivery technology, has raised £1.27M in equity …See details»
Vitarka Therapeutics appoints Dr John Beadle as Chairman of the …
Nov 26, 2024 Vitarka Therapeutics appoints Dr John Beadle as Chairman of the Board. London, 27 November 2024: Vitarka Therapeutics Ltd, the EndoPore® cancer therapeutics company, …See details»
Female led UK biotech start-up secures £1.27m to revolutionise ...
Apr 11, 2023 Data Privacy Policy ... ...See details»